Opinion

Video

Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis

Author(s):

Christopher G. Bunick, MD, PhD,Lindsay S. Ackerman, MD, FAAD

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Video content above is prompted by the following:

  • What is the recommended monitoring schedule for JAKi? Do you communicate it with patients when selecting treatment?
Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Study Highlights Interim Results on Abrocitinib for Adolescents, Adults with Atopic Dermatitis
December 19th 2024

Study Highlights Interim Results on Abrocitinib for Adolescents, Adults with Atopic Dermatitis

Tim Smith
Advances in Pediatric Eczema Highlight 2022
December 21st 2022

Advances in Pediatric Eczema Highlight 2022

Kevin Kunzmann
Coco Dekkers, PhD candidate I Credit: LinkedIn
December 18th 2024

Tralokinumab Effectively Treats Moderate-to-Severe Atopic Dermatitis: Real-World Data

Chelsie Derman
How Pegloticase Plus Methotrexate is Breaking Ground in Gout Care
July 12th 2022

How Pegloticase Plus Methotrexate is Breaking Ground in Gout Care

Armand Butera
Christopher G. Youn, MD Candidate I Credit: Stanford Biosciences
December 18th 2024

Parents of Children with Atopic Dermatitis Often Sleep Less Than 7 Hours

Chelsie Derman
FDA Receives sNDA for Roflumilast Cream Treatment of Children with Atopic Dermatitis
December 16th 2024

FDA Receives sNDA for Roflumilast Cream Treatment of Children with Atopic Dermatitis

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.